Cargando…

LEE011 and ruxolitinib: a synergistic drug combination for natural killer/T-cell lymphoma (NKTCL)

Natural killer/T-cell lymphoma (NKTCL) is an aggressive non-Hodgkin lymphoma that has been facing limited success with conventional treatments, urging for the discovery of alternative strategies. Recent studies including ours have revealed that EZH2 and JAK-STAT signalling pathways are key contribut...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hee, Yan Ting, Yan, Junli, Nizetic, Dean, Chng, Wee-Joo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112754/ https://www.ncbi.nlm.nih.gov/pubmed/30159126 http://dx.doi.org/10.18632/oncotarget.25835

Ejemplares similares

Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer
por: Yuan, Yuan, et al.
Publicado: (2019)

The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation
por: de Mel, Sanjay, et al.
Publicado: (2018)

Kayadiol exerted anticancer effects through p53-mediated ferroptosis in NKTCL cells
por: He, Cuiying, et al.
Publicado: (2022)

Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma
por: Karagianni, Fani, et al.
Publicado: (2021)

EZH2 K63-polyubiquitination affecting migration in extranodal natural killer/T-cell lymphoma
por: Li, Boheng, et al.
Publicado: (2023)

Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)
por: Scheinberg, Tahlia, et al.
Publicado: (2020)

Molecular mechanism of G(1) arrest and cellular senescence induced by LEE011, a novel CDK4/CDK6 inhibitor, in leukemia cells
por: Tao, Yan-Fang, et al.
Publicado: (2017)

Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma
por: Mustafa, Nurulhuda, et al.
Publicado: (2021)

Super-enhancer-driven TOX2 mediates oncogenesis in Natural Killer/T Cell Lymphoma
por: Zhou, Jianbiao, et al.
Publicado: (2023)

VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma
por: He, Hai-Xia, et al.
Publicado: (2021)

Epigenetic aberrations in natural killer/T-cell lymphoma: diagnostic, prognostic and therapeutic implications
por: Küçük, Can, et al.
Publicado: (2020)

RUNX3 is oncogenic in natural killer/T-cell lymphoma and is transcriptionally regulated by MYC
por: Selvarajan, V, et al.
Publicado: (2017)

Signaling for Synergistic Activation of Natural Killer Cells
por: Kwon, Hyung-Joon, et al.
Publicado: (2012)

The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models
por: Kim, Sunkyu, et al.
Publicado: (2018)

Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma
por: Lamoureux, Francois, et al.
Publicado: (2014)

Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models
por: Kim, Sunkyu, et al.
Publicado: (2020)

Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013)

Microcosm 2.011
por: CERN Bulletin
Publicado: (2011)

Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma study group
por: Kim, Seok Jin, et al.
Publicado: (2013)

Implication of Interleukin-12/15/18 and Ruxolitinib in the Phenotype, Proliferation, and Polyfunctionality of Human Cytokine-Preactivated Natural Killer Cells
por: Terrén, Iñigo, et al.
Publicado: (2018)

Antitumoral Activity of the MEK Inhibitor Trametinib (TMT212) Alone and in Combination with the CDK4/6 Inhibitor Ribociclib (LEE011) in Neuroendocrine Tumor Cells In Vitro
por: Jin, Xi-Feng, et al.
Publicado: (2021)

Calreticulin increases growth and progression of natural killer/T-cell lymphoma
por: Zheng, Yan, et al.
Publicado: (2020)

Primary Natural Killer/T-Cell Lymphoma of the Ribs
por: Kim, Kyoung Min, et al.
Publicado: (2023)

T-cell dysfunction in natural killer/T-cell lymphoma
por: Feng, Xiaoyan, et al.
Publicado: (2023)

Macrophages protect mycoplasma‐infected chronic myeloid leukemia cells from natural killer cell killing
por: Choo, Qing Wei Winnie, et al.
Publicado: (2020)

Ruxolitinib synergistically enhances the anti-tumor activity of paclitaxel in human ovarian cancer
por: Han, Ernest S., et al.
Publicado: (2018)

Extranodal Natural-Killer/T-Cell Lymphoma, Nasal Type
por: Gill, Harinder, et al.
Publicado: (2010)

Treatment outcome of nasal natural killer/T-cell lymphoma
por: Lee, Hyun Jin, et al.
Publicado: (2011)

Delayed Diagnosis of Nasal Natural Killer/T-Cell Lymphoma
por: Villwock, Jennifer A., et al.
Publicado: (2013)

Extranodal natural killer/T-cell lymphoma of the tenosynovium of the hand
por: Lim, Yoo Li, et al.
Publicado: (2015)

Pathogenesis and biomarkers of natural killer T cell lymphoma (NKTL)
por: Somasundaram, Nagavalli, et al.
Publicado: (2019)

Advances in multiple omics of natural-killer/T cell lymphoma
por: Xiong, Jie, et al.
Publicado: (2018)

Extranodal Natural Killer/T-Cell Lymphoma: An Incidental Finding
por: Althoff, Ashley, et al.
Publicado: (2017)

Non-coding RNAs in Natural Killer/T-Cell Lymphoma
por: Mei, Mei, et al.
Publicado: (2019)

Updating targets for natural killer/T-cell lymphoma immunotherapy
por: Xue, Weili, et al.
Publicado: (2021)

P011 Antifungal lock therapy
por: Koparkar, Vidyullata, et al.
Publicado: (2022)

Gelsolin regulates proliferation, apoptosis and invasion in natural killer/T-cell lymphoma cells
por: Guo, Yanwei, et al.
Publicado: (2017)

Integrated driver mutations profile of chinese gastrointestinal-natural killer/T-cell lymphoma
por: Li, Shanshan, et al.
Publicado: (2022)

Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma
por: Li, Zhaoming, et al.
Publicado: (2019)

On the Lee-model
por: Kroll, N M
Publicado: (1958)

Cannot write session to /tmp/vufind_sessions/sess_mphkii8pbpjkjou4324o4fkp6k